Drug Type Monoclonal antibody |
Synonyms IFX-2 |
Target |
Action inhibitors |
Mechanism C5a inhibitors(complement C5a inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammation | Preclinical | Germany | 01 Nov 2024 | |
Autoimmune Diseases | Preclinical | Germany | 25 Apr 2020 |